Pulike Biological Engineering, Inc. Class A

Pulike Biological Engineering, Inc. Class A

SSSE:603566
9.05
CNY
-0.04
(-0.44%)
0.25EPS
32.54P/E
3.54BMarket Cap
Apr 23Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.97
1.98
1.65
1.83
1.67
1.88
2.06
2.94
3.51
3.81
3.59
3.03
3.18
2.94
Basic EPS, GAAP
0.68
0.58
0.49
0.59
0.36
0.42
0.34
0.72
0.78
0.52
0.5
0.27
0.54
0.31
Free Cash Flow per Basic Share
0.28
0.36
0.2
0.56
0.26
0.23
0.17
0.27
-0.34
-0.4
-0.06
0.43
0.82
- -
Dividend per Share
- -
0.25
0.17
0.15
0.2
0.2
0.3
0.2
0.5
0.2
0.64
0.4
0.6
0.6
Book Value per Share
2.51
2.85
4.18
4.57
4.85
5.08
5.16
5.32
5.6
7.95
7.72
7.59
7.53
7.36
Tangible Book Value per Share
2.01
2.37
3.46
3.91
4.2
4.4
4.42
4.57
4.69
7.08
6.86
6.73
6.57
6.41
Basic Weighted Avg Shares
240
240
289
319
317
323
321
316
313
323
349
344
343
341
Sales/Revenue/Turnover
472
476
478
583
530
608
663
929
1,099
1,230
1,253
1,043
1,090
1,005
Operating Margin (%)
36.18
33.29
30.53
28.13
16.55
20.23
13.65
23.28
24.68
17.32
17.09
10.62
17.45
10.28
Depreciation Expense
25
31
32
34
37
42
50
51
59
75
93
122
122
- -
Net Income, GAAP
163
140
142
188
114
136
109
228
244
168
175
93
185
107
Effective Tax Rate (%)
15.2
16.03
15.9
14.89
14.36
11.49
6.78
12.41
14.09
5.57
10.33
6.03
10.78
11.74
Profit Margin (%)
34.5
29.48
29.64
32.24
21.55
22.3
16.47
24.53
22.22
13.64
13.93
8.9
16.97
10.69
Working Capital
189
266
824
901
945
765
698
590
388
1,127
901
834
942
1,032
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
1
- -
20
19
Total Equity
603
684
1,337
1,481
1,569
1,645
1,658
1,710
1,800
2,804
2,724
2,626
2,737
2,657
Return on Invested Capital (%)
26.02
20.56
12.87
11.06
6.06
7.57
6.09
12.97
14.1
7.31
6.35
3.51
6.96
3.22
Return on Capital (%)
29.8
21.61
13.62
13.08
7.28
8.46
6.65
13.53
13.91
7.3
6.33
3.47
6.86
4.95
Return on Common Equity (%)
31.21
21.8
14.03
13.34
7.49
8.44
6.61
13.53
13.91
7.29
6.31
3.47
7.07
4.17

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
7
7
7
LT Borrowings
19
18
18
LT Finance Leases
2
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
346
346
346
Market Capitalization
4,277
3,388
3,544

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,406
1,404
1,412
Cash, Cash Equivalents & STI
754
735
801
Accounts Receivable, Net
390
392
389
Inventories
230
241
189
Total Current Liabilities
368
406
379
Payables & Accruals
- -
- -
- -
ST Debt
7
7
7
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.43%
11.76%
4.22%
Free Cash Flow
-79.21%
-191.8%
90.42%
Net Income, GAAP
13.36%
6.49%
99.33%
Sales/Revenue/Turnover
9.66%
3.98%
4.54%
Total Cash Common Dividend
- -
70.61%
48.83%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
235
248
279
281
1,043
2025
279
281
- -
267
1,090
2026
249
242
247
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.08
0.14
0.09
-0.04
0.27
2025
0.16
0.19
- -
0.08
0.54
2026
0.12
0.11
0.01
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.4
2025
- -
- -
- -
0.2
0.6
2026
- -
0.4
- -
- -
- -

Company Description

CEO
Fei Hu
Full Time Employees
1,519
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No.15 Zhenghe Road Luoyang HN China 471000
IPO Date
May 18, 2015
Business
Pulike Biological Engineering, Inc. (603566.SS) engages primarily in the research, development, production and sale of veterinary biological products and drugs; its core offerings encompass vaccines, antibodies and medicines for swine and poultry, alongside disinfectants, chemical preparations and traditional Chinese veterinary medicines; the company further provides vaccines and pharmaceuticals for ruminants including cattle and sheep, as well as for pets, with specific products such as porcine circovirus vaccines, mycoplasma vaccines, swine foot-and-mouth disease vaccines, new-branch-stream trivalent inactivated vaccines, new-branch-reduce-stream quadrivalent inactivated vaccines, chicken infectious bursal disease refined egg yolk antibodies and duck viral hepatitis refined egg yolk antibodies. Founded in 1995 and headquartered in Luoyang, Henan province, China, Pulike Biological Engineering, Inc. operates as a state-level high-tech enterprise with comprehensive strength ranking at the industry forefront; it maintains seven subsidiaries focused on vaccines, chemicals and pets, plus two shareholding companies in vaccines and testing, serving primarily the domestic Chinese animal health market while pursuing international expansion through the Belt and Road initiative. In recent developments, the company anticipates receiving CNY 900 million in funding from a group of investors, bolstering its research and development efforts where it invests over 10% of revenues—equivalent to $178 million in 2022—across more than 150 products produced via six GMP facilities and 50 product lines employing over 1,700 staff including 200 in R&D.